Basel, 6 December 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced its plans to launch the SARS-CoV-2 & Flu A/B Rapid Antigen Test for professional use in markets accepting the CE Mark by the ...

CARLSBAD, Calif., March 19, 2020 (GLOBE NEWSWIRE) -- GenMark Diagnostics, Inc. (NASDAQ:GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, today announced that the ...

Voluntary SARS CoV 2 testing of the hemodialysis population may require incentives beyond varying test frequency. Only 8% of patients voluntarily comply with repeat SARS-CoV-2 testing in hemodialysis ...

SAN DIEGO--(BUSINESS WIRE)--Quidel Corporation (NASDAQ: QDEL) (“Quidel”), a leading provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, ...

(RTTNews) - Roche (RHHBY) announced the launch of the cobas SARS-CoV-2 Variant Set 1 Test to detect and differentiate mutations found in variants that originated in the UK, South Africa, and Brazil.

The SARS-CoV-2 pandemic has prompted extensive developments in diagnostic testing and population surveillance, which are critical tools in mitigating viral spread. Strategies have evolved from ...

The Global Virus Network (GVN), representing eminent human and animal virologists from more than 90 Centers of Excellence and ...

As the COVID-19 virus continues to evolve, here’s what to know about SARS-CoV-2 Variant BA.3.2, the “Cicada" variant.

Since its emergence as a novel pandemic in 2019, SARS-CoV-2 has become endemic worldwide. Accordingly, there is an ongoing market in antigen-based testing for this virus. Microbix's SARS-CoV-2 antigen ...

The term “cicada” is not a scientific designation and has no biological connection to insects. It is an informal nickname used in some media coverage to describe the variant’s apparent re-emergence ...